CT 004
Alternative Names: CT-004Latest Information Update: 27 Jul 2022
At a glance
- Originator Bayer
- Developer Coagulant Therapeutics
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Haemophilia
Most Recent Events
- 18 Jul 2022 CT 004 is available for licensing as of 11 Jul 2022. https://www.coagulanttherapeutics.com/partner
- 11 Jul 2022 Early research in Haemophilia in South Korea (Parenteral)
- 11 Jul 2022 Coagulant Therapeutics plans a phase I trial in Haemorrhage in first half of 2025 (Coagulant Therapeutics pipeline, June 2022)